Real evaluation and clinical data analysis of the therapeutic effect of ritexitinib (Lefenox)

Ritlecitinib is a new type of oral selective dual kinase inhibitor of the JAK3/TEC family, mainly used to treat autoimmune diseases such as alopecia areata (AA). It showed significant efficacy and good safety in the ALLEGRO Phase 2b/3 clinical trial, making it a potential new option for the treatment of severe alopecia areata in adolescents.

In the ALLEGRO study, adolescent patients 12 to 17 years were treated with either 30mg or 50mg of ritixitinib. At week 24, 17% to 28% of the 30 mg and above dose group >patients' SALT scores (proportion of hairless scalp) were reduced to less than 20%, compared with 0% in the placebo group. At week 48, 25% to 50% of patients in the treatment group had a SALT score ≤20, showing sustained efficacy.

In terms of efficacy evaluation, in the ritexitinib treatment group at 24 weeks, 45% to 6 One percent of patients reported "moderate" or "large" improvement, compared with 10% to 22% of patients in the placebo group. At week 48, 44% to 80% of patients in the treatment group continued to improve, indicating stable long-term efficacy.

In terms of safety, common adverse reactions of ritexitinib include headache, acne and nasopharyngitis. No serious adverse reactions such as death, major cardiovascular adverse events, malignant tumors, pulmonary embolism, opportunistic infections or herpes zoster infection were observed in the study, showing good tolerability.

Overall, ritixitinib has demonstrated significant efficacy and good safety in the treatment of severe alopecia areata in adolescents, providing patients with a new treatment option. As more clinical data accumulate, its potential in other autoimmune diseases also deserves further exploration.

Reference materials:https://www.drugs.com/